8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

Current Report Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2016

 

 

Kewaunee Scientific Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-5286   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, NC 28677

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

 

(a) and (b) On August 31, 2016, the Company held its 2016 Annual Meeting of Stockholders. At that meeting, the Company’s shareholders voted on the matters set forth below.

 

1. Each of the nominees named below was re-elected as a Class III director for a three year term as follows:

 

Name of Nominee

   For        Withheld      Non-Votes  

Margaret B. Pyle

     1,833,400           22,989         595,671   

Donald F. Shaw

     1,783,000           73,389         595,671   

 

2. The independent registered accounting firm of Ernst & Young LLP was ratified as the Company’s independent auditor for fiscal year 2017 as follows:

 

For

 

Against

 

Abstained

2,444,167

  5,604   2,289

 

3. The compensation of the Company’s named executive officers was approved on an advisory basis pursuant to the following votes:

 

For

 

Against

 

Abstained

 

Non-Votes

1,776,368

  73,200   6,821   595,671


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 2, 2016

 

Kewaunee Scientific Corporation
By:   /s/ Thomas D. Hull III
  Thomas D. Hull III
  Vice President, Finance and
  Chief Financial Officer